Year None2022202120202019201820172016201520142013 May 21 View HTML version View PDF Version Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol May 20 View HTML version View PDF Version FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis May 13 View HTML version View PDF Version High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair May 4 View HTML version View PDF Version Regeneron Reports First Quarter 2022 Financial and Operating Results May 2 View HTML version View PDF Version Regeneron Announces Investor Conference Presentations Apr 19 View HTML version View PDF Version Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types Apr 14 View HTML version View PDF Version U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19 Apr 7 View HTML version View PDF Version Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation Apr 5 View HTML version View PDF Version Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022 Apr 4 View HTML version View PDF Version FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis Current page 1 Page 2 Page 3 Next page › Last page »